Skip to content
Homepage
Author:
UroGen Pharma Ltd.
Posted Date:
July 15, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
UroGen Pharma Ltd.
July 15, 2026
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd.
July 8, 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd.
June 5, 2026
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
UroGen Pharma Ltd.
June 2, 2026
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
UroGen Pharma Ltd.
June 1, 2026
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Pharma Ltd.
May 15, 2026
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Pharma Ltd.
May 15, 2026
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
UroGen Pharma Ltd.
May 13, 2026
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
UroGen Pharma Ltd.
May 13, 2026
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd.
May 7, 2026
1
2
3
Next
